Home › Cancer types › Lung cancer › Lung cancer with ROS1, BRAF, MET, RET, NTRK, HER2 or NRG1 changes
Lung cancer with ROS1, BRAF, MET, RET, NTRK, HER2 or NRG1 changes
Rarer doesn't mean forgotten. Each of these changes now has targeted options, which is why broad testing matters so much for you.
ℹ️ General information to help you and your loved ones talk with your care team, not medical advice. Read our disclaimer.
The quick guide
What it means: Less common gene changes drive the cancer: ROS1, BRAF V600E, MET exon 14 skipping, RET, NTRK fusions, HER2 (ERBB2) mutations, or NRG1 fusions.
How it's found: Broad gene panels on tissue (ideally including RNA) and/or blood.
How common it is: Each is found in about 1 to 4% of non-small cell lung cancers.
How treatment works
🌱 Early-stage
- Early-stage treatment is usually standard surgery, chemo and immunotherapy; targeted pills are mainly for advanced disease.
🔁 Advanced or metastatic
- ROS1: crizotinib, entrectinib or repotrectinib. BRAF V600E: dabrafenib + trametinib or encorafenib + binimetinib. MET: capmatinib or tepotinib. RET: selpercatinib or pralsetinib. NTRK: larotrectinib or entrectinib. HER2: Enhertu or zongertinib. NRG1 fusions: zenocutuzumab.
Approvals depend on stage and prior treatment. Your care team will decide what fits you.
Drug guides
Biomarker tests that matter
Side effects you may notice
- Fatigue (extreme tiredness)
- Diarrhea (loose, watery stools)
- Nausea and vomiting (CINV)
- Dermatitis (skin rash and skin changes)
❓ Questions you and your loved ones can ask
- Did my test check every one of these genes, including RNA testing?
- Is there a clinical trial for my change?
Back to Lung cancer overview. Other types: EGFR-positive lung cancer, ALK-positive lung cancer, KRAS-positive lung cancer (including G12C), Lung cancer with no driver mutation (PD-L1 guides treatment), Small cell lung cancer (SCLC).
Written by the Cancer Side Effects Guide team from FDA labels and leading cancer centers. Not medical advice. · Last updated: October 15, 2026 · How we write